# Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

> **NCT04205240** · PHASE2 · TERMINATED · sponsor: **Srinivas Devarakonda** · enrollment: 1 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Daratumumab
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT04205240
- **Lead sponsor:** Srinivas Devarakonda
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-22
- **Primary completion:** 2021-05-08
- **Final completion:** 2021-11-22
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04205240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04205240, "Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04205240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*